Sommadossi Jean-Pierre

President, CEO, and Chairman, DirectorAtea Pharmaceuticals, Inc. (AVIR) · full profile →Form 4 · filed Sep 19, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$234K
Net Open-Market Flow
-$234K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 19, 2024Sell(S)2K$4.00$7K5.9M
Sep 18, 2024Sell(S)22K$4.03$89K5.9M
Sep 17, 2024Sell(S)34K$4.05$137K5.9M

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-108233) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about AVIR insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000950170-24-108233"
Ask your agent
Use Arkolith to summarize insider buying and selling at Atea Pharmaceuticals, Inc.
over the last 90 days and cite the filings.